In June 2018, as part of the strengthening of potential export, the St. Petersburg Scientific Research Institute of Vaccines and Serums has successfully passed the certification audit for compliance with antigen production quality for influenza vaccines. Food and Drug Administration of the Islamic Republic of Iran issued the certificate in August of this year. It confirms that the manufacture of vaccines of our Institute is in full accordance with GMP standards.
We would like to remind that in July of 2018, a partner of the Institute, “Petrovax Pharm” company received the license to manufacture (No. LP-004951 of 07.23.2018) for inactivated tetravalent subunit adjuvant vaccines for the prevention of influenza – “Grippol® Quadrivalent”. The vaccine will be produced in Russia using full cycle technology, beginning with the phase of release of substances, including antigens, according to GMP standards in disposable syringes without preservatives. The Vaccine and Serum Scientific Research Institute in this project acts as an influenza vaccine antigen supplier.